GLUT9b- and ABCG2-mediated collecting duct urate transport uncover a vasopressin-independent mechanism of renal water reabsorption
Authors:
- Mohamad HadlaMHMohamad Hadla
- Jean Marc MardirossianJMJean Marc Mardirossian
- Daniel G. BichetDBDaniel G. Bichet
- Abdul Hamid BorgholABAbdul Hamid Borghol
- Georges AbboudGAGeorges Abboud
- Ahmad GhanemAGAhmad Ghanem
- Vicente E. TorresVTVicente E. Torres
- Seth L. AlperSASeth L. Alper
- Volker VallonVVVolker Vallon
- Fouad T. ChebibFCFouad T. Chebib
Open Access
- 16 June 2026
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (14)
Abstract
Renal water reabsorption is classically regulated by vasopressin V2 receptor (V2R) signaling through cyclic AMP and protein kinase A, driving apical accumulation of aquaporin-2 (AQP2). However, collecting duct water handling is also modulated by vasopressin-independent mechanisms. Here, we examined intracellular soluble urate as a vasopressin-independent regulator of AQP2 trafficking. Intracellular urate accumulation in collecting duct cells was mediated by enhanced apical urate uptake via GLUT9b and reduced apical urate efflux through ABCG2, triggering phosphodiesterase-4 activation, reduced cAMP, and downstream AMP-activated protein kinase (AMPK) activation. The resulting AQP2 accumulation at the apical membrane was independent of V2R signaling, required ongoing endocytosis and was associated with features of post-endocytic apical trafficking of internalized AQP2. In vivo ABCG2 inhibition with probenecid increased apical AQP2 abundance and markedly attenuated tolvaptan-induced polyuria in both wild-type and Pkd1 RC/RC autosomal dominant polycystic kidney disease (ADPKD) mice in a uricase-independent manner, while preserving tolvaptan’s ADPKD-modifying efficacy. In a Phase 2 trial with tolvaptan-treated ADPKD patients, probenecid reduced urine volume and nocturia frequency. Together, these findings support a vasopressin-independent urate–AMPK–AQP2 pathway that regulates renal water handling and, in a preclinical ADPKD model, can uncouple cyst growth attenuation from the dose-limiting aquaretic effects of V2R antagonism.Keywords
Funding Information
- Otsuka America (OAK-ISS-2021-001441)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK142878)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK144863)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK137307)
This publication has 67 references indexed in Scilit:
- AQP2 trafficking in health and diseases: an updated overviewThe International Journal of Biochemistry & Cell Biology, 2022
- Urate transport in health and diseaseBest Practice & Research Clinical Rheumatology, 2021
- Simple dietary advice targeting five urinary parameters reduces urinary supersaturation in idiopathic calcium oxalate stone formersUrolithiasis, 2020
- SLC2A9 (GLUT9) mediates urate reabsorption in the mouse kidneyPflügers Archiv - European Journal of Physiology, 2018
- Hyperuricemia enhances intracellular urate accumulation via down-regulation of cell-surface BCRP/ABCG2 expression in vascular endothelial cellsBiochimica et Biophysica Acta (BBA) - Biomembranes, 2018
- Stimulation of V1a receptor increases renal uric acid clearance via urate transporters: insight into pathogenesis of hypouricemia in SIADHClinical and Experimental Nephrology, 2016
- Urate Transporters: An Evolving FieldSeminars in Nephrology, 2011
- Uric Acid: A Danger Signal From the RNA World That May Have a Role in the Epidemic of Obesity, Metabolic Syndrome, and Cardiorenal Disease: Evolutionary ConsiderationsSeminars in Nephrology, 2011
- The effect of probenecid on the renal elimination of cimetidineClinical Pharmacology & Therapeutics, 1989
- Equil2: A Basic Computer Program for the Calculation of Urinary SaturationJournal of Urology, 1985